Inhaled corticosteroids in COPD

Inhaled corticosteroids in COPD: a light at the end of the tunnel?

J A Wedzicha, T A R Seemungal

Some promising findings on the effects of inhaled corticosteroids on mortality in COPD

Chronic obstructive pulmonary disease (COPD) is arguably the most common chronic disease of the lungs at present and, by 2020, it will be the third leading cause of death worldwide. COPD is associated with a relentless decline in forced expiratory volume in 1 second (FEV₁) and, in the later stages, the condition progresses to pulmonary hypertension and hypoxic respiratory failure.

Few interventions have been shown to affect the outcome of COPD. The Lung Health Study-1 (LHS-1) showed that smoking cessation decreases the accelerated decline in FEV₁, characteristic of this disease and, more recently, that smoking cessation is associated with decreases in cardiovascular and lung cancer mortality in patients with COPD. Furthermore, two randomised controlled studies of long term oxygen therapy (LTOT) showed that LTOT improves mortality in patients with COPD complicated by hypoxic respiratory failure.

Because so few interventions have been shown to affect mortality and FEV₁ decline in COPD, two further outcomes have been studied arising from the observed close association between exacerbation frequency and health related quality of life. In the ISOLDE study (Inhaled corticosteroids in Obstructive Lung Disease in Europe), inhaled corticosteroids were shown to slow the decline in health status over time and also to decrease exacerbation frequency. Further statistical modelling has shown that the effect of inhaled corticosteroids on quality of life is largely due to their effect on exacerbation frequency. Recent studies have closed the loop between exacerbation frequency, mortality, and lung function decline by showing that patients with a history of frequent exacerbations have an accelerated decline in FEV₁ and increased mortality from COPD. From these data one would therefore expect that interventions that reduce COPD exacerbations would also reduce COPD mortality.

In this issue of Thorax we publish a study by Sin and colleagues who show, for the first time, that inhaled corticosteroids are associated with a reduction in all-cause mortality in patients with COPD. This study is important for several reasons. Firstly, it represents a major collaboration between academia and industry that allowed a pooled analysis of the original data from all seven longer term randomised controlled studies of the effects of inhaled corticosteroids in COPD. This is a major strength of this study. Secondly, it is one of the few studies to report an intervention that affects all-cause mortality in COPD. Thirdly, this study shows that COPD mortality may be affected before developing end stage disease in COPD. A previous systematic review found no significant effect of inhaled corticosteroids on mortality but confirmed the beneficial effects of inhaled corticosteroids on exacerbation frequency. A recent meta-analysis of eight studies of inhaled corticosteroids (four of which are included in the current report) showed that inhaled corticosteroids decreased the decline in FEV₁, perhaps through their effect on exacerbations. Thus, before the report of Sin and colleagues, the major effect of inhaled corticosteroids in COPD was considered to be on reduction in exacerbations with no clear effect on mortality.

The authors obtained the original anonymised data from each of the seven randomised placebo controlled trials of inhaled corticosteroids of at least 12 months duration. The data were then pooled to form a dataset of 5085 patients with allowance for source effect. The study design is unique, and the authors should be commended for their contribution and effort in this regard. Sin and colleagues showed that inhaled corticosteroids reduced all-cause mortality by 27%, and the effects were more pronounced in women, former smokers, and patients with moderate or severe disease. Sex differences in the natural history of COPD have been recognised for some time, with women showing a faster decline in FEV₁. However, as Sin and colleagues point out in the discussion to the paper, women with COPD have greater bronchial hyperreactivity than men and this factor may be associated with the observation that the effects of inhaled corticosteroids on mortality are more pronounced in women. Further studies are required to confirm these sex differences and to investigate the mechanisms associated with these observations.

As with all post hoc analyses of this type, there are limitations. Firstly, only two of the studies (ISOLDE and LHS-2) included mortality on an intention to treat basis, while in the other five studies mortality data were only available for those who completed the study. These two studies contributed 37% of the patients to the analysis and were also the two longest studies (34 and 42 months, respectively). The effect of ISOLDE and LHS-2 are therefore likely to influence the results more than the other included studies. The contribution of each study to the overall death rate is not shown in the report and the authors refer to this possible source of bias in their discussion. There are also differences in the pre-intervention treatment of patients between the different studies. For example, in the EUROSCOP study there was a 6 month run-in with no treatment but the ISOLDE study and the study by Calverley and colleagues included a run-in period during which patients were treated with oral corticosteroids. Furthermore, the size of the included studies varied because they were each powered to detect different parameters. For example, four of the seven studies were powered to detect a difference in the decline in FEV₁ of 12–20 ml/year between inhaled corticosteroids and placebo controlled groups and all failed to detect a difference, but the meta-analysis by Sutherland et al showed that this difference was in fact much smaller—of the order of 7.7 ml/year. Finally, in all the included studies the difficulty in finding an effect on mortality hitherto has been because of the effect of dropouts. In a further analysis from the ISOLDE study, Calverley and colleagues showed that dropouts were greater in the placebo arm and were associated with a faster decline in FEV₁, thus implying that mortality was probably greater in the placebo arm which has now been supported by Sin et al.

Currently, for patients with COPD, it may no longer be relevant to ask whether inhaled corticosteroids have a role, but the question still remains—which COPD patients should be given inhaled corticosteroids? The ISOLDE study showed that the effects of inhaled corticosteroids on exacerbation frequency were greatest.
for patients with an FEV₁ of <50% predicted. However, the LHS-2 found a 50% decrease in unscheduled physician visits for respiratory illnesses (interpreted as exacerbations) in patients with much milder COPD. A further analysis from the ISOLDE study showed that, when patients with an exacerbation frequency of at least one per year are studied, the effects of inhaled corticosteroids on COPD mortality was statistically significant in patients with FEV₁ <60% but not in those with a higher FEV₁, although we must be careful about subset analysis in a pooled dataset such as this — and the authors have cautioned us appropriately in the paper. However, one of the further important questions that arises from this study and others is the actual dose of inhaled corticosteroids that should be prescribed in COPD and the long term side effects of this dosing.

Inhaled corticosteroids have similar effect sizes on FEV₁ decline in COPD and on exacerbations (7.7 ml/year is about 25% of the expected FEV₁ decline in normal patients, ISOLDE found a 25% effect on reduction in exacerbation frequency). The effect of inhaled corticosteroids on mortality in patients with COPD may therefore be through decreased exacerbation frequency. Intriguingly, Sin and colleagues in their meta-analysis found a trend towards a lower incidence of cancer mortality in the treatment arm; however, cancer deaths in this study were low and the study was not powered to look at specific causes of death. A further larger study is therefore required before clear conclusions can be drawn about the effects of inhaled corticosteroids on specific causes of mortality.

Twelve years ago, one of us writing an editorial in this journal made the point that, despite much work on the role of inhaled corticosteroids in COPD, the results of larger controlled trials of the effects of inhaled corticosteroids on FEV₁ decline and disease progression were keenly awaited. We now recognise that one of the major effects of inhaled corticosteroids in COPD may be through the reduction in the frequency and severity of exacerbations and thus decreasing mortality. In addition to leading to respiratory failure and mortality in more severe disease, COPD exacerbations are associated with increased systemic inflammatory markers such as plasma fibrinogen and C-reactive protein (CRP), so patients with a history of frequent exacerbations may have an increased risk of cardiovascular disease.

In exacerbation frequency in patients with COPD may therefore lead not only to improvements in health status, disease progression and respiratory mortality, but also to a reduction in cardiovascular morbidity and mortality. We now await the results of the TORCH (Towards a Revolution in COPD Health) study of the long term effects of inhaled corticosteroids and long acting bronchodilators (alone and in combination) on mortality in COPD in one of the largest prospective studies ever undertaken on the treatment of COPD — the TORCH light that will now perhaps guide us to the end of the tunnel?"}


Authors' affiliations

J A Wedzicha, Professor of Respiratory Medicine, Royal Free and University College Medical School, Rowland Hill Street, Hampstead, London NW3 2PF, UK; j.a.wedzicha@mdsch.ucl.ac.uk

Competing interests: In the last 3 years JAW has obtained research funding for studies of COPD exacerbations from Glaxo Smith Kline, Astra Zeneca, Boehringer Ingelheim and Aventis Pasteur. She has also received honoraria for lectures or attending advisory boards from Glaxo Smith Kline, Astra Zeneca, Boehringer Ingelheim, Pfizer, Aventis Pasteur, Bayer, Novartis, and Arrow Therapeutics Ltd. TARS has obtained sponsorship to attend international meetings from Glaxo Smith Kline, Astra Zeneca, Boehringer Ingelheim, Pfizer and Merck Sharpe & Dohme and has received honoraria for lectures at meetings organised by all five companies.

Correspondence to: Professor J A Wedzicha, Royal Free and University College Medical School, Rowland Hill Street, Hampstead, London NW3 2PF, UK; j.a.wedzicha@mdsch.ucl.ac.uk

REFERENCES

10 Kanzer RE, Anthonisen NR, Connell J, on behalf of the Lung Health Study. Lower respiratory illnesses promote FEV₁ decline in smokers but not ex-smokers with mild or moderate chronic obstructive pulmonary disease: results from the Lung Health Study. Am J Respir Crit Care Med 2001;164:358–64.
Non-invasive mechanical ventilation: when to start for what benefit?

B Fauroux, F Lofaso

When is the optimal time to perform polysomnography in patients with neuromuscular disease?

Non-invasive ventilation (NIV) is recognised as an efficient therapeutic option in patients with chronic respiratory insufficiency due to neuromuscular disorders. However, the long standing clinical experience with NIV contrasts with the absence of validated criteria for initiating this treatment and the paucity of data on its long term physiological and psychometric effects.

Several consensus conferences agree on the value of daytime hypercapnia and an acute exacerbation as criteria for starting NIV because they are characteristic signs of established ventilatory failure. However, these two classical criteria are preceded by a variable period of nocturnal hypoventilation during which treatable symptoms—such as frequent arousals, severe orthopenic, daytime fatigue, and alterations in cognitive function—may cause deterioration in the quality of the patient’s daily life.

The first problem is to decide when to perform polysomnography in a patient with only a few symptoms. Polysomnography should be undertaken without delay when the patient develops symptoms related to sleep disordered breathing, but patients with neuromuscular disorders tend to underestimate symptoms such as fatigue before using mechanical ventilation. Sleep disordered breathing is difficult to establish in children because of reliance on parents and other caregivers who have a different perception of the child’s disease. Lung function parameters are poor indicators of nocturnal hypoventilation and data are only available for patients with neuromuscular disorders. Indeed, forced expiratory volume in 1 second (FEV₁) has been shown to be inversely correlated with nocturnal hypoventilation and daytime arterial carbon dioxide tension (PaCO₂). A cut-off value for peak transcutaneous carbon dioxide tension (TcCO₂) of 6.5 kPa as a definition of nocturnal hypoventilation differs according to the underlying disease and also in children compared with adults. A definition based exclusively on the PaCO₂ value may be too restrictive and insufficiently relevant from a clinical perspective.

If NIV is proposed earlier in the course of ventilatory failure, it should be accompanied by a significant improvement in measurable symptoms attributable to nocturnal hypoventilation, disruption of sleep architecture, and poor quality of sleep. NIV is able to improve nocturnal gas exchange in patients with neuromuscular disease, cystic fibrosis, obstructive sleep apnoea, both in adults and children. But, in all these studies, patients had overt daytime hypoventilation. NIV initiated according to the “classical criteria” was associated with an improvement in survival in patients with Duchenne muscular dystrophy, but the only study that has evaluated the “preventive” use of NIV in patients with Duchenne muscular dystrophy showed negative results with a significantly greater mortality rate in the NIV group. In this study the main inclusion criteria were a vital capacity of 20–50% of the predicted value and a PaCO₂ value below 6 kPa. The patients did not undergo polysomnography before and after the initiation of NIV and no information was given on the symptoms attributable to sleep disordered breathing. Patients with a variable level of nocturnal hypoventilation could therefore have been included without a control to determine the efficacy of NIV and an objective measure of compliance with its use. This argues for a more precise evaluation of subjective measures (such as symptoms) and objective measures of sleep disordered breathing before initiation of NIV.

In addition to an improvement in nocturnal hypoventilation and survival, it would be highly desirable if the use of PaCO₂. This is attributed to the heating effect of the electrode. Nevertheless, strong correlations have been observed between TcCO₂ and PaCO₂ values and between changes in TcCO₂ and in PaCO₂.

The third difficulty concerns the other indications for nocturnal NIV. As previously discussed, the indication is usually based on a cut-off PaCO₂ value which is transgressed during a defined percentage of the sleep time or the study period. But other respiratory events during sleep—for example, those recently recommended for the diagnosis of sleep related breathing disorders such as sleep fragmentation—may also need to be taken into account. Moreover, it may be possible that the optimal definition of nocturnal hypoventilation differs according to the underlying disease and also in children compared with adults. A definition based exclusively on the PaCO₂ value may be too restrictive and insufficiently relevant from a clinical perspective.

In the study reported by Ward and co-workers in this issue of Thorax, patients were recruited for polysomnography when vital capacity fell below 50% predicted or when symptoms suggestive of nocturnal hypoventilation were present. These screening criteria may be too large. Indeed, even if the authors chose a cut-off value for peak transcutaneous carbon dioxide tension (TcCO₂) of 6.5 kPa as a definition of nocturnal hypoventilation in the absence of daytime hypercapnia, they admitted that, in practice, nearly all patients had a TcCO₂ value of >6.5 kPa for more than 30% of the total study period. Sleep disordered breathing is characterised not only by episodes of hypercapnia but also by desaturations. Nocturnal desaturation is common in patients with respiratory muscle weakness, especially during rapid eye movement (REM) sleep but, here again, no reliable correlation has been established between any lung function parameter and the importance of nocturnal desaturation. Respiratory muscle testing was also performed but the correlation of these data with nocturnal hypoventilation was not available. Thus, neither lung function nor respiratory muscle parameters nor symptoms seem to be sufficiently pertinent for the scheduling of polysomnography in patients with neuromuscular disease. The optimal timing of polysomnography is also unknown in patients with alveolar hypoventilation resulting from other causes such as chronic obstructive pulmonary disease and cystic fibrosis. Although it has been shown that these patients progressively develop rapid shallow breathing as their FEV₁ falls below 50% of the predicted value, no correlation has been established between any index of respiratory function or respiratory muscle performance and the severity of sleep disordered breathing.

The second difficulty concerns the use of TcCO₂ for the diagnosis of hypercapnia. TcCO₂ generally overestimates
“early” NIV was also associated with a significant decrease in acute exacerbations and, in patients with neuromuscular disease and cystic fibrosis, with a slowing in the decrease in lung function and respiratory muscle performance. A delay in acute exacerbations has not been observed in neuromuscular patients and would be very difficult to prove in patients with cystic fibrosis. NIV seems to be associated with a slower rate of decline in pulmonary function in patients with Duchenne muscular dystrophy compared with control subjects, and in children with various neuromuscular disorders. However, in cystic fibrosis, such data are not yet available. In children, particularly those with neuromuscular disorders, it would be interesting to examine whether “early” NIV is associated with better lung growth. Indeed, mechanical forces generated by the contractile activity of the diaphragm and the intercostal muscles have been shown to play an important part in normal lung growth and development in animal models by their effect on cell proliferation.

Two other major aspects of NIV have been poorly studied. Sleep disordered breathing causes impaired cognitive function and is associated with a poor quality of life. These adverse effects may affect the patient’s daily life and the school performances of a child before the occurrence of daytime hypercapnia. Studies of the effect of “early” initiation of NIV should evaluate these outcomes according to the underlying disease and the age of the patient.

In conclusion, having established that NIV can reverse alveolar hypoventilation in patients with neuromuscular and lung disease, the time has come to evaluate, for each disease, the optimal timing for polysomnography—the most pertinent indicator for proposing NIV—and to evaluate its benefits with regard to the course of the disease, stabilisation of lung function and respiratory muscle performance, improvement in cognitive functioning, possible preservation of lung growth in young children and, most importantly, the quality of life of the patient and his/her family.


References


Improving survival in idiopathic PAH

Improveing survival in idiopathic pulmonary arterial hypertension: revisiting the "kingdom of the near-dead"

S Mehta, G J Shoemaker

Recent advances in the treatment of idiopathic PAH have resulted in increased survival

Idiopathic pulmonary arterial hypertension (PAH), formerly known as primary pulmonary hypertension, is characterised by raised pulmonary artery pressure and pulmonary vascular resistance in the absence of underlying significant cardiopulmonary or other medical disease. Idiopathic PAH is a progressive disorder that usually culminates in right ventricular failure and death. Moreover, patients with idiopathic PAH are often severely limited on exertion by dyspnoea and fatigue, and thus suffer from a poor quality of life. Lack of clinical recognition of idiopathic PAH for more than 100 years, there have been few effective therapeutic options until recently. Given the previous absence of effective pharmacological therapy, surgical removal of the disease by lung transplantation has been an important therapeutic option for patients with idiopathic PAH. Lung transplantation is associated with rapid and sustained improvement in pulmonary haemodynamics. Moreover, in individual patients with idiopathic PAH who do not respond to medical treatment, timely lung transplantation will often be associated with improved survival even though long term survival after lung transplantation remains poor.

One of the first long term pharmacological approaches used for treating idiopathic PAH was systemic anticoagulation. In patients with idiopathic PAH, pulmonary microvascular thrombosis is present histologically and there is laboratory evidence of a procoagulant haematological state. Moreover, both retrospective and non-randomised cohort studies have suggested a survival benefit of systemic anticoagulation in idiopathic PAH. Although not formally studied in a randomised controlled trial, systemic anticoagulation is recommended for the majority of patients with PAH in the absence of a clear contraindication based on assessment of individual bleeding risk.

Survival benefit of new treatments in idiopathic PAH

Ongoing basic biological and clinical research has led to tremendous advances in our understanding of the pathobiology of idiopathic PAH. Moreover, an increasing number of novel therapeutic agents targeting these pathobiological features have been studied in randomised clinical trials and many are available and recommended for clinical use in patients with idiopathic PAH. These include prostacyclin derivatives such as intravenous epoprostenol, subcutaneous treprostinil, inhaled iloprost, and oral beraprost, as well as other novel oral pulmonary hypertension treatments such as the non-selective endothelin receptor antagonist bosentan and the phosphodiesterase V inhibitor sildenafil.

These new treatments for pulmonary hypertension have been shown to improve pulmonary haemodynamics as well as clinically relevant end points such as symptoms and functional capacity, objectively measured exercise capacity, and quality of life in many patients with idiopathic PAH. But are such improvements in the morbidity associated with idiopathic PAH enough? Most would agree that improvements in symptoms and functional capacity should not be the only goals. Patients with idiopathic PAH, a disease which is usually fatal, have been suggested to live in a “kingdom of the near-dead”. An improvement in survival has therefore always been an important goal of treatment for both patients and their caregivers. A significant survival benefit has been suggested in patients with idiopathic PAH treated with several agents including oral calcium channel blockers, intravenous epoprostenol, oral beraprost, and oral bosentan (table 1). Chronic treatment with high dose calcium channel blockers was the first to show a survival benefit in these patients. Although treatment of idiopathic PAH with calcium channel blockers has not been assessed in a randomised controlled trial, high dose calcium channel blockers are accepted as first line oral treatment for some patients with idiopathic PAH based on the dramatic survival benefit observed in a non-randomised cohort trial and long term clinical experience. Unfortunately, only a minority of patients with idiopathic PAH (13–27%) demonstrate acute vasodilator responsiveness. Moreover, sustained long term reduction in pulmonary arterial pressure may only be achieved with high dose calcium channel blockers in perhaps half of acute vasodilator responders, so only 7–15% of patients with idiopathic PAH may have improved survival with chronic calcium channel blocker treatment.

For the large majority of idiopathic PAH patients who are not candidates for long term treatment with calcium channel blockers, an increasing number of therapeutic agents are becoming available. In such patients the first alternative was continuous intravenous delivery of epoprostenol. In a landmark study, intravenous epoprostenol treatment was associated with a significant survival benefit compared with standard treatment, although survival was not the primary end point. Several groups have recently published their long term experience confirming a survival benefit of intravenous epoprostenol treatment. A small retrospective study suggests a survival benefit of an oral prostacyclin derivative, beraprost.

The report by Sitbon and colleagues in this issue of Thorax supports a long term survival benefit of treatment with bosentan, the first drug in a new class of pharmacological agents, the endothelin receptor antagonists. Bosentan is the first oral agent specifically approved for treatment of idiopathic PAH in North America, Europe, and other parts of the world. The study by Sitbon et al confirms the survival benefit suggested by an analysis of long term, open label bosentan treatment in idiopathic PAH patients enrolled in the original two randomised controlled trials.

It is apparent that none of the studies of pulmonary hypertension specific treatments were placebo controlled, double blind randomised controlled trials and all suffer from several methodological limitations, some major (table 1). These include a lack of randomisation, non-blinding of patients and investigators to the active treatment, and limited power as many studies assessed fewer than 50 patients. In addition, all studies are limited by either a complete absence of a control group or the use of a control group other than a placebo treated cohort. Moreover, the basis of the survival advantage in
several studies is a comparison of observed survival in a treated cohort of patients with idiopathic PAH with their expected survival which is based on haemodynamic severity of pulmonary hypertension and calculated from a reference equation derived from patients with idiopathic PAH in the National Institutes of Health (NIH) Registry.22 23 Since patients in the NIH Registry were managed at recognized US pulmonary hypertension centers between 1981 and 1985, other differences and advances in the quality of care—both recognised (such as more widespread current use of systemic anticoagulation) and unrecognised—may bias in favour of the survival of contemporary cohorts, independent of the treatment under study.

Despite the above limitations, most would accept that several of the new treatments do indeed increase survival of patients with idiopathic PAH. It is noteworthy that trials of new treatments for pulmonary hypertension have largely enrolled idiopathic PAH patients with the most advanced disease (WHO functional class III and IV). Thus, survival benefit with the newer treatments may not necessarily be seen in idiopathic PAH patients with earlier WHO class I and II functional status and will clearly be harder to demonstrate, given the longer natural history of disease in such patients. Furthermore, all trials have included patients on other treatments that may independently modify survival, including systemic anticoagulation.24 This approach of concomitant treatment with two or more agents addressing different pathological pathways is the future of pulmonary hypertension treatment and several formal combination treatment trials are in progress.

**FUTURE THERAPEUTIC DIRECTIONS IN PAH**

Unfortunately, the limitations in the studies described will probably be propagated in future studies. It would clearly be unethical to perform a placebo controlled trial of a new treatment for pulmonary hypertension with survival as an end point. Moreover, the increasing availability of effective oral treatment will make recruitment more difficult for future placebo controlled trials. Studies will increasingly compare the effects of new agents with those of established agents, as in the study by Sitbon et al in this issue which compared survival in bosentan treated and epoprostenol treated patients. The focus of clinical trials of new PAH treatments is also broadening to include increasing numbers of patients with other types of pulmonary hypertension such as PAH secondary to connective tissue disease or congenital heart disease. However, large groups of patients with pulmonary hypertension remain unstudied and largely untreated, such as those with inoperable chronic thromboembolic pulmonary hypertension and pulmonary hypertension due to underlying cardiac or pulmonary disease.

Finally, given the difficulty in assessing a survival benefit, what other end points should we assess in future trials of new treatments for pulmonary hypertension? Quality of life is an important end point as pulmonary hypertension is associated with severe symptoms and functional limitation, and objective measurement tools are being developed. The symptoms, exercise limitation, and poor prognosis in pulmonary hypertension relate closely to the impairment of right ventricular function. Direct assessment of right ventricular size and function with new imaging approaches (such as three-dimensional echocardiography or MRI) and haemodynamic measurements (such as during exercise) will facilitate assessment of the severity of idiopathic PAH and quantify the decline over time or response to treatment. Moreover, new biological and genetic markers related to the pathobiology of pulmonary hypertension are currently being studied and may be useful parameters for diagnosis, assessment of severity, and guiding therapeutic decisions.

Patients with idiopathic PAH have clearly benefited from tremendous advances in the science and practice of pulmonary hypertension. However, many other patients with pulmonary hypertension have yet to benefit from the new treatments. We expect that treatments for pulmonary hypertension currently available and being developed will also lead to improvements in the quality of life, right ventricular function, and

### Table 1 Studies reporting improved survival with pulmonary hypertension specific treatment in patients with idiopathic PAH

<table>
<thead>
<tr>
<th>Reference</th>
<th>Treatment</th>
<th>Active treatment group [n]</th>
<th>WHO class (I/II/III/IV) n</th>
<th>Observed survival (%)</th>
<th>Expected/control survival (%)</th>
<th>Details/limitations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rich’</td>
<td>Oral CCB</td>
<td>17</td>
<td>N/A</td>
<td>94 94 94</td>
<td>68 47 38</td>
<td>Prospective open label cohort; 17/64 patients selected for chronic CCB based on acute CCB response; survival with chronic CCB compared with acute non-responders (n = 47) and NIH Registry cohort</td>
</tr>
<tr>
<td>Sitbon ’</td>
<td>Oral CCB</td>
<td>38</td>
<td>0/22/16/0</td>
<td>100 97 97 97</td>
<td>71 66 62 48</td>
<td>Retrospective review of 70/557 patients selected for chronic CCB based on acute vasodilator response; survival of chronic CCB responders (n = 38) compared with chronic CCB failures (n = 32)</td>
</tr>
<tr>
<td>Bors’</td>
<td>IV apoprostol</td>
<td>41</td>
<td>0/0/31/10</td>
<td>100</td>
<td>80</td>
<td>Prospective open label cohort; survival compared with predicted survival based on NIH equation</td>
</tr>
<tr>
<td>Kuhn’</td>
<td>IV apoprostol</td>
<td>41</td>
<td>0/0/19/22</td>
<td>85 76 65</td>
<td>62 49 39</td>
<td>Prospective open label cohort; survival compared with predicted survival based on NIH equation</td>
</tr>
<tr>
<td>McLaughlin’</td>
<td>IV apoprostenol</td>
<td>162</td>
<td>0/0/75/87</td>
<td>88 76 63</td>
<td>59 46 35</td>
<td>Prospective open label cohort; survival compared with predicted survival based on NIH equation</td>
</tr>
<tr>
<td>Sitbon ’</td>
<td>IV apoprostol</td>
<td>178</td>
<td>0/0/120/58</td>
<td>85 70 63 55</td>
<td>58 43 33 28</td>
<td>Prospective open label cohort; survival compared with WHO matched historical cohort (n = 125)</td>
</tr>
<tr>
<td>Nagoya’</td>
<td>Oral beraprost</td>
<td>24</td>
<td>0/0/22/2</td>
<td>96 86 76</td>
<td>77 47 44</td>
<td>Retrospective review of single centre experience; survival compared with WHO matched historical cohort (n = 34)</td>
</tr>
<tr>
<td>McLaughlin’</td>
<td>Oral bosentan</td>
<td>169</td>
<td>2/13/139/15</td>
<td>96 89 86</td>
<td>69 57 48</td>
<td>Prospective open label cohort; survival compared with predicted survival based on NIH equation</td>
</tr>
<tr>
<td>Sitbon ’</td>
<td>Oral bosentan</td>
<td>139</td>
<td>0/0/139/0</td>
<td>97 91</td>
<td>91 84</td>
<td>Prospective open label cohort; survival compared with concurrent or historical apoprostol treated cohorts (n = 346)</td>
</tr>
</tbody>
</table>

Data represent mean values.

PAH, pulmonary arterial hypertension; m, months; y, years; IV, intravenous; N/A, not available; CCB, calcium channel blockers.
Pulmonary hypertension after splenectomy

Pulmonary hypertension after splenectomy: a consequence of loss of the splenic filter or is there something more?

A J Peacock

The exact mechanism by which pulmonary hypertension develops after splenectomy remains unclear

Pulmonary arterial hypertension is a syndrome—not a disease—and has a number of causes. In these cases there is a wide range of pathoetiologies such as HIV infection, portopulmonary hypertension, intracardiac shunt, chronic thromboembolic disease, hypoxic lung disease, connective tissue disease, idiopathic pulmonary hypertension, and familial pulmonary hypertension associated with mutation of the BMPR2 gene.

In this issue of *Thorax*, Jais et al have examined the clinical background of 257 patients referred to their centre for treatment of chronic thromboembolic pulmonary hypertension (CTEPH). They found that 8.6% of the patients had a history of splenectomy compared with 2.5% of patients with idiopathic pulmonary hypertension (IPH) and 0.4% in the general population. They concluded that splenectomy alone had caused thromboembolism and hence the pulmonary hypertension in these patients. But is this true?

Chronic thromboembolic disease has been defined as ‘pulmonary hypertension caused by the absence of thrombus resolution after acute pulmonary embolism which has resulted in sustained obstruction of the pulmonary circulation’. This view is probably outdated because in 50% of cases there is no definite history of venous thrombosis and it is likely that many cases are a consequence of in situ thrombosis. Bonderman et al have recently looked at the medical conditions that increased the risk of CTEPH in 109 consecutive patients and found that splenectomy increased the relative risk of this condition by a factor of 13.

The findings of Jais et al and Bonderman et al are not new—for example, Hoeper et al found an 11.5% incidence of splenectomy in 61 patients with pulmonary hypertension. In the papers by Jais et al and Hoeper et al it appears that splenectomy increases the risk of both IPH and CTEPH. For example, Jais et al found an incidence of splenectomy of 2.5% even in the patients with IPH. Interestingly, of the 22/257 with CTEPH who had had splenectomy, only eight were suitable for treatment by the standard operation of thromboendarterectomy, which suggests that they had distal disease. This raises the issue of the continuity between CTEPH, the thrombotic variant of IPH, and small vessel IPH

**REFERENCES**

without thrombosis. It may well be that the primary problem is not simply one of increased coagulability due to loss of the splenic filter but one of abnormal endothelial surface resulting in situ thrombosis or another factor. Certainly, in IPH the survival can be doubled simply by the use of warfarin and, in these cases, there is no history of venous thromboembolism. The simplest explanation for the finding of Jais et al11 and of the other authors who have studied this problem is that following splenectomy, there is both thrombocytosis and also increased numbers of damaged circulating red cells which will activate these platelets. There is also no increased capacity of the red cells to generate thrombin. This phenomenon was discovered in patients with thalassaemia intermedia, but there is a number of reports of CTEPH in patients with other haemolytic disorders—for example, pyruvate kinase deficiency,4 congenital spherocytosis,5 and stomatocytosis.6 The complicating factor is that, for many of these conditions, splenectomy is a treatment and therefore it is difficult to differentiate between hypercoagulability caused by the splenectomy per se and hypercoagulability caused by the underlying haemolytic disease. Furthermore, we do not know whether it is simply the prothrombotic component of the disease that is important or whether there is some other factor which could lead to pulmonary hyper tension separately from pulmonary vascular thrombosis. For example, haemoglobin released from haemolysed red cells present in the plasma would scavenge nitric oxide which is an important pulmonary vasodilator.

Certainly, when splenectomy is performed to treat a haemolytic disorder, the combination of the haemolytic disorder and the splenectomy seem to increase the likelihood of pulmonary thromboembolism further, due in part to the excess thrombin generated by the abnormal red cells. Cappellini et al12 studied a large group of adults with both thalassaemia intermedia and thalassaemia major for up to 10 years and found a high prevalence of thromboembolic events, particularly in the splenectomised patients, which was associated with an enhanced capacity to generate thrombin by the thalassaemic red cells. This enhanced capacity was not seen in patients who had a splenectomy for other reasons—that is, it was not a function of the splenectomy per se. It is likely, however, that the splenectomy exacerbated the situation by the reduced clearance of abnormal red cells. This would suggest that, in many cases, it is not splenectomy alone which causes the problem but splenectomy in the face of an underlying haemolytic disorder. There is some evidence for this view. Boxer et al13 studied 318 otherwise fit patients who had been treated by splenectomy and found that 75% had increased platelet levels immediately following the operation but there were no increased incidence of venous thromboembolism. This may be because the thrombocytosis normally diminishes following splenectomy and it is only if it persists that the pulmonary hypertension develops. For example, Rostagno et al14 described a patient who suffered CTEPH associated with long standing thrombocytosis but, when the thrombocytosis was treated, there was improvement in both the clinical state and in the pulmonary haemodynamics. Marvin and Spellberg15 described another patient who had thrombocytosis and developed pulmonary hypertension and right heart failure following splenectomy, but treatment of the thrombocytosis with hydroxyurea improved both vascular and cardiac function.

The finding that splenectomy alone seems to be benign, but that splenectomy in the face of an underlying haemolytic disorder results in a high incidence of pulmonary hypertension (for example, Aessopos et al16 found that 59% of patients with thalassaemia intermedia who had had splenectomy developed thromboembolic pulmonary hypertension) suggests that it is a combination of the two factors—namely, an abnormality of red cells (and possibly platelets) and splenectomy—that leads to pulmonary hypertension and in situ thrombosis. However, there is other evidence that splenectomy can cause pulmonary hypertension in patients who do not have haemolytic disorders. For example, Elstein et al17 showed that, in 134 patients with Gaucher’s disease, 7% had pulmonary hypertension detected by echocardiography. It is interesting that most of these had been treated by splenectomy. In the paper by Jais et al11 in this issue of Thorax only four of the 22 patients who developed CTEPH after splenectomy had a haemolytic disorder, and in most of the others the spleen had been removed for trauma.

What is of great interest is the long time interval (range 2–35 years) between the splenectomy in the patients studied by Jais et al11 and the development of thromboembolic pulmonary hypertension. This suggests either that the development of pulmonary hypertension is a very slow process or that some additional factor developed which resulted in a prothrombotic state, perhaps a change in endothelial function or a change in red cell characteristics. From the above it is clear that splenectomy is a risk for thromboembolic hypertension, particularly in patients who have had splenectomy for a haemolytic disorder. It is also clear that clinicians should watch these patients carefully and consider whether long term anticoagulation would be appropriate. We should also keep an eye on patients who have had splenectomy for other reasons—that is, it was not apparent from the development of pulmonary hypertension. The exact mechanism by which pulmonary hypertension develops after splenectomy, even in patients with underlying haemolytic disorders, remains unclear but provides a fascinating model for future research.

doi: 10.1136/thx.200X.043216

Correspondence to: Professor A J Peacock, Scottish Pulmonary Vascular Unit, Western Infirmary, Glasgow G11 6NT, UK; apeacock@uddl.gla.ac.uk

REFERENCES

Paediatric respiratory mortality

Radical new ideas are needed to ensure that deaths from respiratory diseases in children continue to fall

Paediatric respiratory mortality: past triumphs, future challenges

G Russell

The invitation to comment on a paper that reports changes which occurred during a period that coincided, within a year or two, with my career as a consultant paediatrician presents me with an irresistible temptation to reminisce. At medical school in the late 1950s I learned that pneumonia, one time captain of the men of death, had responded dramatically first to sulphonamides and then to penicillin, but that some deaths were still “inevitable”—a phrase much used at that time to excuse our inability to manage conditions that we did not fully understand. Asthma was common in children but was considered to be an unusual cause of death, although it was responsible for the first death I encountered as a paediatric senior house officer. In the minds of my teachers asthma was readily distinguished from bronchitis and, to this day, I can replicate a table listing the differences between asthma and wheezy bronchitis, most of which has—to my surprise—turned out to be accurate.1 In those far off days most children died while still colonised with Pseudomonas species were not the problem they are now and most children died while still colonised with Staphylococcus aureus or Haemophilus influenzae. Bronchiolitis was considered to be rather an esoteric diagnosis for which there was no diagnostic test—it would be a few years before its association with the respiratory syncytial virus (RSV) was appreciated.2 It was thought safer to diagnose pneumonia if crackles were prominent and to treat the child with antibiotics, while those with predominant wheeze were labelled “bronchitis” and given ephedrine.

In the mid 1960s I extracted data from the Registrar General’s annual reports when, as a junior, I presented a fatal case of staphylococcal bronchopneumonia to a clinico-pathological conference. I was surprised to find not only that there was still considerable childhood mortality from pneumonia but also that, following the rapid decline already mentioned, it had been more or less stable for the previous decade. In my presentation I attributed this to the emergence of penicillin resistant S aureus, an organism that had become ubiquitous despite the widespread presence of gimlet-eyed matrons who, some politicians would have us believe, have the power to stop the more recently emerged methicillin resistant S aureus in its tracks.

By 1968, the first year of the study by Panickar et al3 reported in this issue of Thorax, major changes were afoot. Coincident with—but not necessarily due to—the development of new antibiotics, pneumonia mortality had begun to fall, and when I prepared a figure to illustrate a chapter in a textbook it was clear that mortality from pneumonia was back on its downward track, on which it has remained despite the emergence of respiratory pathogens of vastly greater virulence and antibiotic resistance than anything we had to deal with 40 years ago. Some children with CF were now entering secondary school, although their survival there was usually brief. Overnight incarceration in mist tents was part of the burden borne by patients with CF; in 1968 I was trying to raise money to purchase tents and was still doing so a few years later when Archie Norman demonstrated their inefficacy.4 Antibiotic treatment had improved but nutritional management was woefully inadequate; looking back, it is hard to believe that the era of the Allan diet5 had not even arrived, far less departed. However, by 1968 we were becoming more secure in the diagnosis of bronchiolitis, although we had to rely on rising antibody titres to demonstrate the presence of RSV; the immunofluorescent technique for the rapid diagnosis of RSV infection was described in 19686 but would not be in widespread use for several years. In the absence of an organised system of paediatric intensive care units, the availability of artificial ventilation depended on the interest and enthusiasm of local anaesthetists and paediatricians. Asthma was also a continuing problem; salbutamol was announced that year7 but was not yet available for clinical use, and inhaled corticosteroids were a few years over the horizon.8 The study by Panickar et al9 therefore covers a period during which there were major developments in what we now regard as basic aspects of the management of respiratory tract diseases.

RESPIRATORY DISEASES STUDIED

Pneumonia

The improving mortality from pneumonia reflects many medical advances other than new antibiotics. Panickar et al9 emphasise the importance of immunisations, to which I would add the developments in the organisation and delivery of paediatric intensive care that have occurred in recent years. Nevertheless, there are no grounds for complacency. Children are still dying from pneumonia, and although we have useful guidelines for the management of community acquired pneumonia10—albeit derived from a somewhat scanty evidence base—the management and, perhaps more importantly, the prevention of nosocomial pneumonia remains problematical.

Asthma

However, pneumonia is not the only important cause of respiratory mortality in children. Although fewer than 5% of asthma deaths occur in childhood,12 asthma is an eminently treatable condition and our objective should be to reduce this figure to zero. Most asthmatic children who reach hospital alive will survive, the majority of deaths occurring outside hospital.13 Management in the community is therefore of prime importance. Although there is controversy about the role of written management plans in improving asthma care,14 there is no doubt that comprehensive asthma management programmes are effective in reducing asthma morbidity and hospital admissions.15 The problem is not that we don’t know what to do, but that the very patients who need to be included in such programmes—and in whom much of the childhood asthma morbidity and mortality occurs—are hard to reach because of socioeconomic deprivation,16 family problems, and psychological factors17 that lead to failure to recognise the severity of an attack and failure to seek medical help in time.

Cystic fibrosis

It is already well known that the mortality from CF has fallen to the extent that it is no longer an important cause of childhood death.18 This improvement has, however, been bought at a considerable price in terms of parental stress19 and family disruption20—stress that was described at a recent meeting as “the daily grind.”21 Moreover, socioeconomic deprivation has a substantial adverse impact on the outcome for patients with CF,22 as evidenced for instance by the
Acute viral bronchiolitis

The last major cause of paediatric respiratory death discussed by Panickar et al is acute viral bronchiolitis. The antiviral drug ribavirin, given as a small particle aerosol, has failed to live up to early expectations and is unlikely to have had much influence on mortality. The use of palivizumab, an effective monoclonal antibody directed against RSV, is reserved for high risk cases and is unlikely to have had much influence for the large excess in female mortality.

In addition to applying the medical advances that must sooner or later flow from our increased understanding of the molecular biology of CF, future challenges include narrowing the gender gap in mortality, improved delivery of care to economically disadvantaged families, and reduction of the psychosocial impact of the CF child on other family members.

IMPLICATIONS OF STUDY FINDINGS

So what are the lessons to be learned from this report on childhood mortality? Clearly, paediatric respirologists are getting results at least as satisfactory as those of their colleagues in other paediatric specialties. Deaths are at an all-time low, and for this we can allow ourselves a moment’s satisfaction. However, much remains to be done. One obvious need is for well designed clinical trials in almost every aspect of paediatric respirology, to allow us to fine-hone our management and to discard useless treatments. In particular, although the excellent results obtained in CF in the absence of a satisfactory evidence base testify to the value of clinical experience and common sense in directing patient care, our use of ever more expensive and complex treatments must in future be more rationally based.

However, one challenge that will tax our ingenuity and for which no obvious solution is in sight is the delivery of health education and medical care to families from socially disadvantaged backgrounds. Many governments have pledged to reduce social inequalities in health, but this goal remains elusive. As we have seen, paediatric respiratory medicine is by no means immune to the problems; there will be little benefit from screening for CF or improving asthma management plans if our attempts to deliver appropriate care are frustrated by socioeconomic and psychological barriers. Paediatricians are accustomed to working in multidisciplinary teams, but perhaps it is time to reconsider the composition of such teams which, in the past, have tended to be disease-specific. Should we be making better use of the more generic facilities of the school health service, the social work department, or the clinical psychology department? Whatever the ultimate solution, it is clear that current practice is inadequate and that radical new ideas are needed.
We have now completed three years of our editorship and this past year has been the busiest, but also very rewarding. We are pleased to let you know that, over the past year, Thorax has continued to flourish as a successful high quality respiratory journal.

One of the highlights of the year has been that our impact factor has risen from 4.188 in 2003 to 5.040 for 2004 (table 1). The impact factor that was published in 2005 reflects the number of citations in 2004 divided by the number of original papers and reviews published in Thorax in 2002 and 2003. Thorax is the second highest ranked respiratory journal in terms of impact factor, behind the American Journal of Respiratory and Critical Care Medicine. The number of articles (excluding editorials and letters) published in Thorax has remained relatively constant, with 183 articles in 2001, 210 in 2002, 198 in 2003, and 195 in 2004. Thus, the improvement in the impact factor has reflected the increased number of citations in the medical literature to Thorax papers and this is a result of the high quality papers that you have sent to the journal and the rigour of our peer review process. Over the past year the number of submissions to the journal was at 1503, of which 913 were full original papers and the remainder were editorials, reviews, case reports, Images in Thorax, and letters. Table 2 shows the geographical spread of submissions to Thorax over the past 6 years. The numbers of papers coming from the UK, Europe (excluding UK), Japan and Australasia have remained steady while, over the past year, we have observed a welcome increase in submissions from North America, Canada, and Asia. Our acceptance rate for original research papers now stands at 15% and, for case reports and "Images in Thorax", our acceptance rate is only 6.25%.

We would like to thank all the many reviewers who have given up their valuable time to assess papers for Thorax and contributed to the success of the journal. A list of all the reviewers for the journal during the past 12 months is published after this editorial. During the year, 1402 reviews on Thorax papers were returned by 784 reviewers. Table 3 shows the origin of reviewers by country: 40.4% were from the UK, 23.3% from other areas of Europe excluding the UK, 23.9% from the USA and Canada, and 8.7% from Australasia. We would particularly like to encourage new reviewers to come forward from Asia, Japan, South America, and Africa where the number of Thorax reviewers at present is particularly low. Please register on the Thorax submission website or contact the editors directly. We would particularly like to thank our two statistical reviewers who, between them, have reviewed carefully every potentially acceptable manuscript with statistical data during the year, which amounts to about 350 papers and revisions. Rigorous statistical review in addition to peer review has considerably improved the quality of the final manuscript published in the journal.

This year we have also provided some guidance on the requirements for publication of genetic association studies in Thorax. We noticed that many studies submitted have been underpowered or poorly designed, and we have published an editorial containing guidance on some of the key issues that need to be addressed when assessing the validity of genetic association studies. Already the standard of genetics papers in the journal has improved, and we urge our authors to study these requirements.

We have continued to develop our educational features, including Airwaves at the front of the journal, Lung Alerts (short summaries of papers published in general and non-respiratory journals and serviced by our younger readers), and "Images in Thorax." This series has proved very popular and educational and we have received 111 high quality submissions for the Images series over the year. The series has been available free of charge since November 2003 in a collection on the Thorax website (http://thorax.bmjournals.com/cgi/collection/images). We also published a report on the British Thoracic Society Winter meeting held in London in December 2004. This year we have completed review series on aspects of γ-antitrypsin deficiency, sleep disordered breathing, and pulmonary hypertension in chronic obstructive pulmonary disease (COPD), and epithelial growth factor. Finally, for our researchers we published a useful editorial about obtaining research grant funding.

The Thorax website (www.thoraxjnl.com) has proved very popular and our 10 most frequently read articles online over the past year had a total of 129 004 accesses either as full text, PDF versions, or abstracts. This is a rise of 23% in the accesses to the 10 most frequently read papers online compared with the previous year at 104 602.

Another important innovation in the journal this year has been the Online First service where original articles are posted on the Thorax website soon after acceptance, before technical editing and before publishing in the print version. Although our publication lag for the print journal is still very short (3 months), authors of research papers want their articles cited as soon as possible after acceptance so that their results can influence further research and findings can be incorporated swiftly into clinical practice to the benefit of respiratory patients all over the world.

Correspondence is an important part of Thorax and reflects the activity and interest in the journal. The number of letters to the editor submitted has increased from 99 last year to 109 this year; these consist of letters in response to published articles, research letters that are peer reviewed, and letters about specific clinical cases. There is also the facility to respond online to a published article by "e" letter, which is a useful tool for ensuring continued dialogue around papers published in Thorax. In view of the importance of letters in Thorax, we have recently appointed a specific letters editor whose remit is to coordinate all the correspondence in the journal and on the website.

Thorax editorials have been popular with our readers and the journal regards them as important educational content. Over the past year we published 52 editorials.
and we would particularly like to thank all the authors who have agreed to write these—often at short notice. Fortunately, very few of you have turned down a request to write an editorial for Thorax.

We would like to thank all the Associate Editors who have provided expert help in selecting the best papers for publication and to the Lung Alert, Letters, and "Images in Thorax" editors for their hard work in making sure these features are of high quality and keeping to our tight publication deadlines. We are also grateful to our International Advisory Board for their support of the journal. During the year we held two meetings: one in November 2004 in London with all the Editors and Associate Editors and another with the Thorax Advisory Board at the American Thoracic Society (ATS) meeting in San Diego, USA in May 2005. Above all, we would like to thank all our authors who have sent us such high quality papers for review in the journal—please continue to send us your very best papers.

There are a number of respiratory journals now available and, as editors, we have all faced various complex issues and often difficult decisions regarding papers and particularly issues around publication ethics. In Thorax we have felt for some time that joint meetings of the editors and journal staff of the various respiratory journals would be very beneficial and supportive to us all. Thus, we were delighted when the other editors were enthusiastic about this idea and the first meeting was held at the ATS in May 2005, with a follow up meeting at the ERS (European Respiratory Society) in September 2005. We covered much ground with lively discussion around issues of mutual interest, got to know each other, and are developing our terms of reference for further meetings.

Andrea Horgan, the Managing Editor of Thorax, Ed Howard, the Development Editor, and Julia Cresswell have performed a superb job in running the journal and we are very grateful to them for all the support and advice they have provided us over the year. We would like to thank Liz Stockman, our Technical Editor, for preparing the monthly issues always to the highest standard and for chasing us so keenly to meet all the publication deadlines. Finally, we would like to thank Ed Neville, Sheila Edwards, and the BTS for their support of Thorax over the year.

As you can see from this report, it has been an exceptionally full and very successful year for the journal with a number of interesting developments. The high submission rates over the years 2004 and 2005 will ensure that we will be able to publish high quality papers in the coming year and build on the success achieved with Thorax. We are also interested to hear directly from our readers about any suggestions for improving the journal or its website. To this end, we are keenly to meet all the publication deadlines.

References


Table 2 Geographical distribution of submissions

<table>
<thead>
<tr>
<th>Country</th>
<th>2000</th>
<th>2001</th>
<th>2002</th>
<th>2003</th>
<th>2004</th>
<th>2005</th>
</tr>
</thead>
<tbody>
<tr>
<td>UK</td>
<td>348</td>
<td>323</td>
<td>325</td>
<td>378</td>
<td>398</td>
<td>373</td>
</tr>
<tr>
<td>Europe (excluding UK)</td>
<td>310</td>
<td>386</td>
<td>329</td>
<td>437</td>
<td>527</td>
<td>525</td>
</tr>
<tr>
<td>USA &amp; Canada</td>
<td>87</td>
<td>68</td>
<td>74</td>
<td>126</td>
<td>146</td>
<td>187</td>
</tr>
<tr>
<td>Japan</td>
<td>56</td>
<td>69</td>
<td>74</td>
<td>99</td>
<td>107</td>
<td>100</td>
</tr>
<tr>
<td>Australasia</td>
<td>60</td>
<td>57</td>
<td>45</td>
<td>67</td>
<td>85</td>
<td>76</td>
</tr>
<tr>
<td>Asia</td>
<td>39</td>
<td>26</td>
<td>41</td>
<td>85</td>
<td>125</td>
<td>165</td>
</tr>
<tr>
<td>South America</td>
<td>5</td>
<td>7</td>
<td>6</td>
<td>21</td>
<td>23</td>
<td>25</td>
</tr>
<tr>
<td>Africa</td>
<td>4</td>
<td>5</td>
<td>1</td>
<td>6</td>
<td>11</td>
<td>18</td>
</tr>
<tr>
<td>Middle East</td>
<td>13</td>
<td>24</td>
<td>21</td>
<td>21</td>
<td>26</td>
<td>35</td>
</tr>
</tbody>
</table>

Table 3 Country of origin of reviewers

<table>
<thead>
<tr>
<th>Country</th>
<th>No</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>UK</td>
<td>317</td>
<td>40.4</td>
</tr>
<tr>
<td>Europe (excluding UK)</td>
<td>183</td>
<td>23.3</td>
</tr>
<tr>
<td>USA &amp; Canada</td>
<td>187</td>
<td>23.9</td>
</tr>
<tr>
<td>Japan</td>
<td>4</td>
<td>0.5</td>
</tr>
<tr>
<td>Australasia</td>
<td>8.7</td>
<td>8.7</td>
</tr>
<tr>
<td>Asia</td>
<td>10</td>
<td>1.3</td>
</tr>
<tr>
<td>South America</td>
<td>5</td>
<td>0.6</td>
</tr>
<tr>
<td>Africa</td>
<td>5</td>
<td>0.6</td>
</tr>
<tr>
<td>Middle East</td>
<td>5</td>
<td>0.6</td>
</tr>
<tr>
<td>Total</td>
<td>784</td>
<td>100</td>
</tr>
</tbody>
</table>

Reviewers 1 October 2004 to 30 September 2005

S D Aaron, Canada
E A Adam, Australia
R T Abboud, Canada
F J Accurso, USA
U Ackermann-Liebrich, Switzerland
S G Adams, USA
B J Addis, UK
R Agius, UK
A Agusti, Spain
M Aitken, USA
F O Alabi, USA
M Alberts, USA
W I Al-Daraji, UK
S Aldington, New Zealand
A Aliverti, Italy
J A Al-Tawfiq, Saudi Arabia
K Alving, Sweden
R A Aly, Turkey
B T Ameredes, USA
J Anderson, UK
R R Anderson, UK
S Anderson, Australia
J Angrill, Spain
K A Alving, Sweden
J A Al-Tawfiq, Saudi Arabia
A Aliverti, Italy
S N Baatout, Belgium
P Baas, Netherlands
J Ayres, UK
N Ayas, Canada
J Ayres, UK
P Baas, Netherlands
S N Baatout, Belgium
A Boas, Italy
D Baldwin, UK
I Ballfour-Lynn, UK
M Ballmann, Germany
J Balme, USA
D Banerjee, UK
G Barbaro, Italy
F Barbe, Spain
J Barben, Switzerland
P G Bardin, Australia
R D Barker, UK
N Barnes, UK
P J Barnes, UK
T W Barnes, USA
A Bast, Netherlands
E D Bateman, South Africa
T T Bauer, Germany
C S Beardmore, UK
R Beasley, New Zealand
R Beck, Israel
L E Becket, New Zealand
B Beckett, USA
E H Bel, Netherlands
S C Bell, Australia
D Bellamy, UK
F Bellemare, Canada
G Bellingan, UK
C Benden, UK
B G Benden, USA
N Berend, Australia
R M Bernsen, UAE
J D Best, Australia
A Bhowmik, UK
D Hilton, UK
S S Birring, UK
P N Black, New Zealand
J D Blakey, UK
J M Bland, UK
F Blasi, Italy
A Boehler, Switzerland
G Bolte, Germany
H Booth, UK
G Bothamley, UK
J Bott, UK
L-P Boulet, Canada
J Bourbeau, Canada
D Bouros, Greece
H A Boushey, USA
M Bower, UK
R P Bowler, USA
R J Boyton, UK
P L Brand, Netherlands
C Braun-Fahrlander, Switzerland
S Bretegat, France
C E Brightling, UK
C Brindici, Italy
J Britton, UK
S Brown, UK
V Brusasco, Italy
R Buchdahl, UK
A T Burge, Australia
P S Burge, UK
P R Burge, France
C Burger, USA
P G J Burney, UK
G Burns, UK
A Bush, UK
B K Butland, UK
S Bydder, Australia
C A Byrnes, New Zealand
E J Calderon, Spain
J M Calver, UK
C A Camargo Jr, USA
M Carby, UK
A-L Caress, UK
K C L Carlsen, Norway
W D Carroll, UK
P Cassano, USA
R Castile, USA
M Cazzola, Italy
J C Celedon, USA
D S Celedermajer, Australia
B Chakrabarti, UK
R C Chambers, UK
C K Chan, Canada
P Chanez, France
A B Chang, Australia
M Chan-Yeung, Hong Kong
A J Chauhan, UK
Y Chen, Canada
N S Cherniack, USA
S K Chhabra, India
E R Chilvers, UK
S Chinn, UK
S-H Cho, Republic of Korea
F Chu, UK
F Chung, UK
A Churg, Canada
P J Ciclitira, UK
P A Cistulli, Australia
C Clark, UK
J Cleland, UK
J D Cockcroft, Canada
R K Coker, UK
G L Colice, USA
d Collie, UK
A M Condliffe, UK
G J Connnett, UK
S P Conway, UK
D G Cook, UK
A Cooner, UK
P Cooper, Ecuador
M Corey, Canada
C J Corrigan, UK
P Corris, UK
M G Cosio, Canada
H O Coxson, Canada
J Crane, New Zealand
D D Creer, UK
P Cullinan, UK
S Cunningham, UK
E Dagli, Turkey
M Dohsia, USA
S E K Dahlbom, Sweden
M R Danzigs, USA
A Darzi, UK
C Davidson, UK
J M David, UK
J Davies, UK
C Davison, UK
J Davies, UK
A Davies, UK
P D Davies, UK
R J O Davies, UK
E Daviskas, Australia
P A de Jong, Netherlands
J C de Jongste, Netherlands
R de Marco, Italy
A de Soyaux, USA
M Decramer, Belgium
E Dei Cas, France
R Dekhuijzen, Netherlands
D dellino, USA
F Della Torre, Italy
M Denton, UK
F Detterbeck, USA
K Dheda, UK
A H Diacon, South Africa
P Dilworth, UK
G Dimopoulos, Greece
R Dinwiddie, UK
A Dirksen, Denmark
R Djukanovic, UK
D Dockrell, UK
G Doering, Germany
E Dompel, Netherlands
G Donaldson, UK
K Donaldson, UK
S H Donaldson, USA
E Donnelly, UK
J F Donohue, USA
R L Dorner, UK
N Douglas, UK
J A Douglass, Australia
I J Doull, UK
G H Downie, USA
C Dowson, New Zealand
F Drobniewski, UK
R du Bois, UK
M G Duerrden, UK
K Duncan, UK
D Dugger, UK
L Dupont, Belgium
R Dweik, UK
J E Earis, UK
K M Eastham, UK
P R Eastwood, Australia
E Eber, Austria
E Edell, USA
W Eder, Germany
A M Edwards, UK
R Effros, USA
J J Egan, Eire
N M Eiser, UK
H M El Sahly, USA
S L Elkin, UK
M Elliott, UK
P Ellwood, New Zealand
P Enright, USA
P Ernst, Canada
S C Erzurum, USA
T Evans, UK
M Everard, UK
C F Everett, UK
L Fairclough, UK
A Faith, UK
I Fajac, France
L Fan, USA
R Farr, Spain
D J Farrel, UK
P M Farrel, USA
B Fauroux, France
M Feldmann, UK
K A Ferguson, Canada
D Fergsson, New Zealand
M Ferrer, Spain
A Fisher, UK
D Fishwick, UK
J W Fitting, Switzerland
M F Fitzpatrick, Canada
D Fleming, UK
www.thoraxjnl.com
Inhaled corticosteroids in COPD: a light at the end of the tunnel?

J A Wedzicha and T A R Seemungal

Thorax 2005 60: 977-978
doi: 10.1136/thx.2005.053454

Updated information and services can be found at:
http://thorax.bmj.com/content/60/12/977.1

These include:

References
This article cites 23 articles, 10 of which you can access for free at:
http://thorax.bmj.com/content/60/12/977.1#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

- Epidemiologic studies (1829)
- Drugs: respiratory system (526)
- Health education (1223)
- Smoking (1037)
- Smoking cessation (154)
- Tobacco use (1039)
- Health effects of tobacco use (211)
- Pulmonary hypertension (205)
- Airway biology (1100)
- Clinical trials (epidemiology) (557)
- Lung function (773)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/